featured
Tralokinumab for Moderate to Severe Atopic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The British Journal of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tralokinumab for Moderate-to-Severe Atopic Dermatitis: Results From Two 52-Week, Randomized, Double-Blind, Multicentre, Placebo-Controlled Phase III Trials (ECZTRA 1 and ECZTRA 2)
Br J Dermatol 2020 Sep 30;[EPub Ahead of Print], A Wollenberg, A Blauvelt, E Guttman-Yassky, M Worm, C Lynde, JP Lacour, L Spelman, N Katoh, H Saeki, Y Poulin, A Lesiak, L Kircik, SH Cho, P Herranz, MJ Cork, K Peris, LA Steffensen, B Bang, A Kuznetsova, TN Jensen, ML Østerdal, EL Simpson, ECZTRA 1 and ECZTRA 2 study investigatorsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.